{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:17:44Z","timestamp":1759335464957},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Surg Oncol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s13193-021-01401-w","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:02:25Z","timestamp":1627862545000},"page":"208-215","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Revisiting Combination Chemotherapy as a Single Modality Palliative Therapy for Advanced Anaplastic Thyroid Carcinoma\u2014a Single Institution Experience"],"prefix":"10.1007","volume":"13","author":[{"given":"Surabhi","family":"Garg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasi","family":"Mouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kul Ranjan","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Ramakant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand K.","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chanchal","family":"Rana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,2]]},"reference":[{"issue":"3","key":"1401_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.critrevonc.2012.10.006","volume":"86","author":"XS Sun","year":"2013","unstructured":"Sun XS, Sun SR, Guevara N et al (2013) Chemo radiation in anaplastic thyroid carcinomas. Crit Rev Oncol\/ Haematol 86(3):290\u2013301","journal-title":"Crit Rev Oncol\/ Haematol"},{"issue":"3","key":"1401_CR2","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/thy.2020.0944","volume":"31","author":"KC Bible","year":"2021","unstructured":"Bible KC, Kebebew E, Brierley J, Brito JP, Cabanillas ME, Clark TJ Jr, Di Cristofano A, Foote R, Giordano T, Kasperbauer J, Newbold K, Nikiforov YE, Randolph G, Rosenthal MS, Sawka AM, Shah M, Shaha A, Smallridge R, Wong-Clark CK (2021 Mar) 2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 31(3):337\u2013386","journal-title":"Thyroid."},{"issue":"5","key":"1401_CR3","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/COC.0b013e31816a61f3","volume":"31","author":"J Chen","year":"2008","unstructured":"Chen J, Tward JD, Shrieve DC, Hitchcock YJ (2008) Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma. Am J Clin Oncol 31(5):460\u2013464","journal-title":"Am J Clin Oncol"},{"key":"1401_CR4","doi-asserted-by":"crossref","unstructured":"Sharifi A, Shojaeifard A, Soroush A, Jafari M, Abdehgah AG, Mahmoudzade H (2016) Predictors of regional lymph node recurrence after initial thyroidectomy in patients with thyroid cancer. J Thyroid Rese 2016: 4127278","DOI":"10.1155\/2016\/4127278"},{"issue":"9","key":"1401_CR5","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1002\/1097-0142(19851101)56:9<2155::AID-CNCR2820560903>3.0.CO;2-E","volume":"56","author":"K Shimaoka","year":"1985","unstructured":"Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R (1985) A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56(9):2155\u20132160","journal-title":"Cancer"},{"issue":"1","key":"1401_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1089\/thy.2009.0115","volume":"20","author":"T Higashiyama","year":"2010","unstructured":"Higashiyama T, Ito Y, Hirokawa M et al (2010) Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid 20(1):7\u201314","journal-title":"Thyroid"},{"key":"1401_CR7","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s002680020166","volume":"25","author":"I Sugitani","year":"2001","unstructured":"Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A (2001) Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg. 25:617\u201322","journal-title":"World J Surg."},{"issue":"7","key":"1401_CR8","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1002\/cncr.20936","volume":"103","author":"E Kebebew","year":"2005","unstructured":"Kebebew E, Greenspan FS, Clark OH, Woeber KA (2005) McMillan A Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. . Cancer. 103(7):1330","journal-title":"Cancer."},{"issue":"6","key":"1401_CR9","doi-asserted-by":"publisher","first-page":"793","DOI":"10.4103\/ijem.IJEM_264_18","volume":"22","author":"R Pradhan","year":"2018","unstructured":"Pradhan R, Agarwal A, Lal P et al (2018) Clinico-pathological profile of anaplastic thyroid carcinoma in an endemic goiter area. Indian J Endocrinol Metab. 22(6):793\u2013797. https:\/\/doi.org\/10.4103\/ijem.IJEM_264_18","journal-title":"Indian J Endocrinol Metab."},{"key":"1401_CR10","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/sj.bjc.6600361","volume":"86","author":"J Tennvall","year":"2002","unstructured":"Tennvall J, Lundell G, Wahlberg P, Bergenfelz A, Grimelius L, Akerman M et al (2002) Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer. 86:1848\u201353","journal-title":"Br J Cancer."},{"key":"1401_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/1097-0142(20000701)89:1<202::AID-CNCR27>3.0.CO;2-A","volume":"89","author":"SA Hundahl","year":"2000","unstructured":"Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J et al (2000) Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer. 89:202\u201317","journal-title":"Cancer."},{"key":"1401_CR12","doi-asserted-by":"publisher","first-page":"542358","DOI":"10.1155\/2011\/542358","volume":"2011","author":"G Nagaiah","year":"2011","unstructured":"Nagaiah G, Hossain A, Mooney CJ, Parmentier J, Remick SC (2011) Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol. 2011:542358","journal-title":"J Oncol."},{"key":"1401_CR13","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1023\/A:1008322002520","volume":"11","author":"D Giuffrida","year":"2000","unstructured":"Giuffrida D, Gharib H (2000) Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann Oncol. 11:1083\u20139","journal-title":"Ann Oncol."},{"issue":"6","key":"1401_CR14","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/0959-8049(96)00069-X","volume":"32","author":"M Lehnert","year":"1996","unstructured":"Lehnert M (1996) Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer. 32(6):912\u2013920","journal-title":"Eur J Cancer."},{"issue":"3","key":"1401_CR15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/BF03348135","volume":"10","author":"S Ahuja","year":"1987","unstructured":"Ahuja S, Ernst H (1987) Chemotherapy of thyroid carcinoma. J Endocrinol Invest. 10(3):303\u2013310","journal-title":"J Endocrinol Invest."},{"issue":"7","key":"1401_CR16","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1089\/thy.2000.10.587","volume":"10","author":"KB Ain","year":"2000","unstructured":"Ain KB, Egorin MJ, DeSimone PA (2000) Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid. 10(7):587\u2013594","journal-title":"Thyroid."},{"key":"1401_CR17","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.2147\/OTT.S153759","volume":"11","author":"Q Xia","year":"2018","unstructured":"Xia Q, Wang W, Xu J, Chen X, Zhong Z, Sun C (2018) Evidence from an updated meta-analysis of the prognostic impacts of postoperative radiotherapy and chemotherapy in patients with anaplastic thyroid carcinoma. Onco Targets Ther. 11:2251\u20132257","journal-title":"Onco Targets Ther."},{"key":"1401_CR18","doi-asserted-by":"crossref","unstructured":"Sosa JA, Elisei R, Jarzab B, et al (2010) Randomized phase 2\/3 trial of a tunor vascular disrupting agent, fosbertubulin (CA4P), with carboplatin(C), and paclitaxel(P) in anaplastic thyroid cancer(ATC): interim safety and efficacy results of the FACT trial. Milan, Italy","DOI":"10.1200\/jco.2011.29.15_suppl.5502"},{"key":"1401_CR19","doi-asserted-by":"crossref","unstructured":"Koussis H, Scola A, Tonello S et al (2006) Multimodality therapeutic approach in anaplastic thyroid cancer (ATC): study of 56 patients. J Clin Oncol. 24(18S, supplement)\u00a0ASCO Annual Meeting Proceedings Part I. Vol. 24","DOI":"10.1200\/jco.2006.24.18_suppl.5571"},{"issue":"11","key":"1401_CR20","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/BF03345066","volume":"23","author":"B Busnardo","year":"2000","unstructured":"Busnardo B, Daniele O, Pelizzo MR et al (2000) A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients. J Endocrinol Investig. 23(11):755\u2013761","journal-title":"J Endocrinol Investig."},{"key":"1401_CR21","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.clon.2010.03.013","volume":"22","author":"RC Smallridge","year":"2010","unstructured":"Smallridge RC, Copland JA (2010) Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol 22:486\u2013497","journal-title":"Clin Oncol"}],"container-title":["Indian Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13193-021-01401-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13193-021-01401-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13193-021-01401-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T12:29:08Z","timestamp":1649248148000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13193-021-01401-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,2]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1401"],"URL":"https:\/\/doi.org\/10.1007\/s13193-021-01401-w","relation":{},"ISSN":["0975-7651","0976-6952"],"issn-type":[{"value":"0975-7651","type":"print"},{"value":"0976-6952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,2]]},"assertion":[{"value":"6 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}